Fig. 4.

Plasma CXCL11 in HNSCC patients upon radio(chemo)therapy (n = 17). A ELISA measurements revealed significantly increased CXCL11 levels in patients that unfortunately ‘died’ during the course of therapy (n = 5) and in patients that received ‘no therapy’ due to a bad health condition (n = 7) compared to healthy donors (n = 10). B CXCL11 measurements revealed no significant differences between the pre and post therapy situation or healthy donors. C Individual plasma CXCL11 pre and post therapy values (ng/ml) revealed decreases as well as increases upon radio(chemo)therapeutic treatment. D CXCL11 levels of HNSCC patients that received only radiotherapy (RT) vs. HNSCC patients that received radiochemotherapy (RCT). Our data revealed that radiotherapy resulted in increased CXCL11 levels in some HNSCC patients, whereas radiochemotherapy resulted only in decreased CXCL11 levels. E Plasma CXCL11 levels of HPV positive vs. HPV negative HNSCC patients. Data revealed significantly increased CXCL11 levels in HPV + patients compared to healthy donors, but not in HPV negative individuals. F Plasma CXCL11 levels of HNSCC patients that received only RTC therapy vs. HNSCC patients that received RTC therapy + surgery. *: p < 0.05; **: p < 0.01. ns: not significant